c-MET
c-Met (METor MNNG HOS Transforming gene) is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR; RTK class X, HGF receptor family). It was originally identified as an oncogene activated in vitro after treatment of a human osteogenic sarcoma (HOS) cell line[1]. Currently, c-Met receives great interest for its role of aberrant signaling in tumorigenesis, particularly in the development of the invasive and metastatic phenotypes (see also Axon 2240). Signaling via the Met–HGF/SF pathway has been shown to lead to a wide range of biological activities including proliferation (mitosis), scattering (motility), and branching morphogenesis, embryological development, wound healing, tissue regeneration, angiogenesis, growth, invasion, and morphogenic differentiation[2].
[1] Molecular cloning of a new transforming gene from a chemically transformed human cell line. C.S. Cooper, M. Park, D.G. Blair et al. Nature 1984, 311, 29–33.
[2] M. Jeffers, L. Schmidt, N. Nakaigawa, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA. 1997, 94, 11445–11450.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3946 | Altiratinib | Balanced inhibitor for MET, TIE2 (TEK), and VEGFR2 (KDR) kinases | Inquire | |
| 1916 | AMG 208 | Inhibitor of c-MET receptor tyrosine kinase (RTK) | €95.00 | |
| 3945 | AMG-337 | Potent and exquisitely selective inhibitor of wild-type and some mutant forms of c-Met | Inquire | |
| 2368 | Amuvatinib | RTK inhibitor which effectively inhibits PDGFR, c-Kit and c-Met | €105.00 | |
| 1838 | ARQ 197 | c-MET tyrosine kinase Inhibitor | €90.00 | |
| 4040 | BMS-777607 | potent, selective and orally bioavailable c-Met inhibitor | Inquire | |
| 1819 | Cabozantinib S-malate | Inhibitor of multiple receptor tyrosine kinases, specifically MET and VEGFR2 | €60.00 | |
| 3423 | Capmatinib | Highly potent, selective, ATP competitive and orally bioavailable c-MET inhibitor | €80.00 | |
| 1660 | Crizotinib | c-MET Inhibitor; NPM-ALK inhibitor | €70.00 | |
| 1582 | Foretinib | c-MET and VEGFR2 tyrosine kinase inhibitor | €90.00 | |
| 1959 | Golvatinib | Potent and orally available inhibitor of c-MET (HGFR) and VEGFR2 | €90.00 | |
| 2553 | LY 2801653 | Orally bioavailable multi-kinase inhibitor with potent activity against c-MET | €120.00 | |
| 3975 | MGCD265 dihydrochloride | Orally active, potent MET/SMO dual inhibitor | €130.00 | |
| 1583 | PF 04217903 mesylate | c-MET tyrosine kinase Inhibitor | €80.00 | |
| 1914 | SGX 523 | ATP-competitive inhibitor of c-MET | €120.00 | |
| 1581 | SU 11274 | ATP-competitive inhibitor of c-MET | €90.00 | |
| 3864 | Volitinib dihydrochloride | ATP-competitive small molecule c-Met kinase inhibitor | Inquire | |